Nexstim

50 articles about Nexstim

• Nexstim Receives an Order for Two NBT® Systems from Canada

  12/14/2022

  Nexstim Plc announces that it has received an order for two NBT® systems through Canadian Health Solutions, the Company’s distributor in Canada.

• Nexstim NBS 5+ System Continues to Generate Interest in the US

  10/6/2022

  Nexstim Plc announces that Drs. Lauren Marangell and Rayan Al Jurdi, experts in the treatment of major depression, have purchased a NBS 5+ system.

• Nexstim Receives an NBS 5+ System Order from Seattle Children’s Hospital

  6/2/2022

  Nexstim Plc announced it has received an NBS 5+ system order from Seattle Children’s in the United States.

• Nexstim Plc to license technology to US-based medical technology company Magnus Medical, Inc. for the treatment of neuropsychiatric disorders

  2/14/2022

  Nexstim Plc announces it has signed an agreement to license technology it has developed to Magnus Medical, Inc., a US-based medical technology company.

• Nexstim Releases the New NBS5+ in the United States

  10/22/2021

  Nexstim Plc announces the launch of a new navigated transcranial magnetic stimulation system configuration in the United States, to further strengthen competitive advantage in this market.

• Nexstim Extends Agreement with Canadian Distributor and Receives Order for Three NBT® Systems

  5/25/2021

  Nexstim Plc announces that it has extended its agreement with Canadian Health Solutions group, the Company’s distributor in Canada, for an additional five years.

• Nexstim Plc supports 10th International Symposium on Navigated Brain Stimulation in Neurosurgery and Neuromodulation

  9/28/2018

  Nexstim Plc today announces its support  for the 10th International Symposium on Navigated Brain Stimulation (NBS) which will be held on 12-13 October 2018 in Berlin, Germany.

• Nexstim Plc Receives R&D Loan From Business Finland

  1/23/2018

  To enable extensive therapeutic use of the NBT System, the project is a major part of Nexstim's commercialisation process of its therapeutic products.

• Nexstim: Issuance of Shares Pursuant to the Restricted Share Unit Reward Plan

  12/14/2017

  The Company has today resolved on issuing altogether 9,910 new shares without payment to two members of the Board of Directors.

• Nexstim's Financial Information in 2018

  12/13/2017

  Nexstim's Annual Report 2017 will be published on the Company's website on Wednesday, March 7, 2018.

• Nexstim Plc Appoints Steve Beller as Vice President and General Manager, North America

  12/1/2017

  Mr. Beller will join the Nexstim Management Team and report to CEO Martin Jamieson.

• 

  Nexstim Gains FDA Clearance to Commercialize Its NBT System to Treat Depression

  11/14/2017

  The NBT system uses a unique method of TMS known as navigated Transcranial Magnetic Stimulation.

• Nexstim Raises EUR 1.75 Million Via a Directed Issue of New Shares to London-Based Investor City Financial - Funds to be Used to Support Beginning The Commercialisation of Its NBT System

  10/25/2017

  The new shares are expected to be registered with the Finnish Trade Register on or about 30 October 2017.

• The Board of Directors of Nexstim Plc Resolved on Amendments of the Stock Options 2016 and on a New Stock Option Plan for the CEO

  10/19/2017

  Nexstim's Board of Directors resolved on May 25, 2016 to issue stock options to the key employees and consultants of the company and its subsidiaries.

• Change In Nexstim's Management Team

  10/12/2017

• Nexstim Half-Yearly Report 1 January - 30 June 2017 (Unaudited)

  8/16/2017

• Notice Of Nexstim's Half-Yearly Report H1 2017

  8/11/2017

• Changes In Nexstim's Management Team

  8/3/2017

• Nexstim Files 510(K) Submission For Its NBT System For The Treatment Of Depression With U.S. FDA

  6/27/2017

• Nexstim Release: Issuance Of New Shares To The Finnish Innovation Fund Sitra Pursuant To The Financing Arrangement Announced On 21 July 2016

  6/7/2017